Acrivon Therapeutics(ACRV) - 2025 Q4 - Annual Results

Financial Position - As of December 31, 2025, Acrivon Therapeutics reported preliminary unaudited cash, cash equivalents, and investments of approximately $119 million, expected to fund operations into Q2 2027[6] Clinical Trials and Research - In the ACR-368 Phase 2b trial, an updated interim analysis showed an overall response rate (ORR) of 39% in monotherapy BM+ subjects, with a higher ORR of 44% in subjects with ≤2 prior lines of therapy[11] - The clinical trial application for Arm 3 of the ACR-368 trial in serous subjects has been submitted, with initial patient enrollment in the EU expected in Q1 2026[11] - ACR-2316, a potential first-in-class WEE1/PKMYT1 inhibitor, has shown clinical activity with tumor shrinkage in 9 out of 20 evaluable patients[14] - ACR-6840, a potential first-in-class CDK11 inhibitor, is anticipated to have an IND submission in Q4 2026[14] - The company plans to complete enrollment in the biopsy-independent Phase 2 Arm 3 trial for ACR-368, targeting 90 subjects, by Q4 2026[17] - Acrivon aims to achieve readiness for a Phase 3 confirmatory trial for ACR-368 in combination with PD-1 therapy by mid-2026[17] - Initial clinical data from the ACR-2316 study will be reported in 1H 2026, transitioning into dose expansion in select tumor types[17] - The company has identified several promising backup series for ACR-6840, which was designed to achieve optimal on-target pathway effects[14] - Acrivon continues to focus on selected, AP3-prioritized solid tumor types in its ongoing clinical trials[14]